CRISPR Technology Challenges from Hype Stage to Market

CRISPR Technology Challenges from Hype Stage to Market

CRISPR is an up-and-coming technology to solve medical problems. However, serious ‎challenges have made the technology to be still at the hype stage, and new approaches ‎are required to implement this technology.‎

CRISPR can be considered as one of the great achievements of biotechnology over ‎the past years, which is a technology that can be used to edit the genome. This ‎technology has opened up new horizons and capabilities from treating cancer and ‎Alzheimer to solving genetic problems.‎

The articles about CRISPR are full of exciting ideas. Some researchers have modified ‎the malaria mosquitoes with CRISPR to eliminate pathogenicity, and some seek to ‎alter the genes of the fetus to give birth to a newborn with desired characteristics. ‎Reviewing the articles in this area offers many such ideas, but could this technology ‎be close to commercialization?‎


CRISPR technology seems to be still at the hype stage, as many of its achievements ‎are now in the laboratory, and a lot of development is needed before it gets ready to ‎enter the market.‎

One of the main obstacles to commercialize CRISPR is health-related safety ‎concerns. CRISPR cut and edit the genome like a scissor, so any error in the ‎performance can lead to severe problems, such as cancer or dangerous changes in the ‎human genome.  ‎

The second challenge is the low effectiveness of this technology. To use this ‎technology for medical purposes, it is necessary to increase the efficiency to the ‎extent that the medical community recognize this technology as an effective tool, ‎while this technology still faces too many errors.‎

Another bottleneck of the commercialization of this technology is that CRISPR can't ‎get where it needs to go. Great attention has been devoted to the use of nanowires for ‎the exact delivery of this editor. In order to use CRISPR in such sensitive areas as the ‎brain, which is protected by a powerful protective barrier, nano-carriers are required ‎that can deceive the brain blood barrier and pass through. A lot of research is needed ‎to overcome this problem.

Despite the high potential of CRISPR, this technology is still at the initial stage of ‎research, and the technology is at the hype stage. Consequently, a broad spectrum of ‎studies is necessary to introduce this technology into markets.‎